GLP-1 Receptor
GLP-1 signaling contributes to satiety and glucose-dependent insulin responses. Lower food intake is one route through which a dual agonist may influence weight.
Back to Peptide Library
Dual Receptor Agonist
Survodutide
BI 456906 • Glucagon / GLP-1 • Liver & Metabolic Research
Survodutide is an investigational once-weekly glucagon and GLP-1 receptor dual agonist. Human trials address obesity, type 2 diabetes, and fatty liver disease, with gastrointestinal tolerability an important part of the evidence.
At a glance
Survodutide Quick Reference
- SYNCHRONIZE-1 targets
- Members onlySign in to view dosing details.
- Research route
- SubQ injectionClinical trials
- Study duration
- Members onlySign in to view dosing details.
- Research focus
- Obesity, liver fat, and MASHSee cited research below
Overview
What Is Survodutide?
Survodutide, also known as BI 456906, combines glucagon and GLP-1 receptor activity. Its development program examines weight reduction alongside liver-related metabolic disease. It shares two receptor targets with mazdutide, but the molecules and clinical programs are distinct.
SYNCHRONIZE-1 studied adults with obesity without diabetes for 76 weeks. Average weight changes under the treatment-regimen analysis were −12.2% at 3.6mg and −13.0% at 6mg, versus −5.4% with placebo. That analysis incorporates discontinuation and other treatment changes. SYNCHRONIZE-1 trial.
The liver program adds another reason to follow the compound. Researchers assess liver fat, MASH histology, and fibrosis as different outcomes; a change in one does not automatically establish a change in the others. Survodutide remains investigational in the cited development program.
Mechanism
Survodutide Mechanism of Action
Glucagon Receptor
Glucagon activity adds a hepatic and energy-metabolism pathway. The intended effect depends on the balance of both receptor activities, not glucagon signaling in isolation.
Liver-Fat Pathway
Phase 3 SYNCHRONIZE-MASLD evaluated liver-fat content with MRI-PDFF. Imaging responses are useful but are not the same endpoint as biopsy-proven fibrosis improvement. SYNCHRONIZE-MASLD trial.
Dose and Tolerability
Clinical exposure is built through escalation. Gastrointestinal effects can influence adherence and the difference between results during treatment and results that include discontinuation.
Research findings
Survodutide Benefits
Results below describe studied populations and formulations. Trial endpoints and analyses matter when comparing outcomes.
Evidence: randomized human clinical trials
Weight Reduction
SYNCHRONIZE-1 demonstrated greater average weight loss than placebo at both weekly targets over 76 weeks.
MASH Histology
In a 48-week Phase 2 trial, MASH improved without worsening fibrosis in 47%, 62%, and 43% at 2.4mg, 4.8mg, and 6mg, versus 14% with placebo. MASH Phase 2 trial.
Liver-Fat Imaging
SYNCHRONIZE-MASLD reported a ≥30% liver-fat reduction in 84.2% at 6mg versus 24.3% with placebo under its efficacy estimand; the treatment-regimen result was lower.
Diabetes Research
New Phase 3 work also evaluates adults with obesity and type 2 diabetes. This is a distinct population from SYNCHRONIZE-1. SYNCHRONIZE-2 trial.
Protocol planning
Survodutide Dosing Protocol
Members Access Only
Sign in or create a free account to view this content.
Preparation
Survodutide Reconstitution
Reconstitution Example
10mg vial + 2mL BAC water
Result5mg/mL
Reconstitution steps
1
Prepare
Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.
2
Add diluent slowly
Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.
3
Dissolve gently
Swirl or roll the vial until the contents dissolve; do not shake.
4
Storage
Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.
N=1 reports
Survodutide Community Experience
Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.
Discussion & Research Interest
- Liver-focused interest. The combination of obesity and liver trials gives researchers more than a scale-weight story to follow.
- Dual-agonist comparisons. Discussion often compares its glucagon/GLP-1 profile with mazdutide and retatrutide.
- Objective tracking. Weight, waist, intake, symptoms, and clinician-interpreted labs are more informative than a broad “liver support” impression.
Limitations & Mixed Interpretation
- Tolerability uncertainty. GI symptoms can limit adherence and make experiences differ markedly.
- Unverified products. Community reports rarely establish the identity or exposure of the trial formulation.
- Endpoint confusion. Less liver fat does not necessarily mean resolved MASH or improved fibrosis.
Stacking & synergy
Survodutide Stacking & Synergy
The comparisons below are research context, not validated combination protocols. Overlapping receptor activity can add risk without demonstrated benefit.
Survodutide + Mazdutide
A research comparison: both target GLP-1 and glucagon. Their matching target names do not make them dose-equivalent or support combining them.
Survodutide + Retatrutide
Retatrutide adds GIP agonism. Cross-trial results can inform questions, but they do not establish superiority or a safe combined regimen.
Survodutide + ATX-304
A separate metabolic research pathway sometimes discussed alongside weight-loss compounds. No controlled Survodutide combination evidence establishes benefit.
Safety notes
Survodutide Side Effects & Safety
Gastrointestinal tolerability is a central limitation. In the Phase 2 MASH study, nausea occurred in 66%, diarrhea in 49%, and vomiting in 41% of Survodutide recipients, versus 23%, 23%, and 4% with placebo.
Adverse effects and interactions require evaluation for the exact compound and formulation.
Safety & Tolerability
- Nausea, diarrhea, and vomiting were frequent in the Phase 2 MASH study.
- GI adverse events were common in the Phase 3 obesity study.
- Reduced intake and fluid losses can complicate nutrition and hydration.
Unresolved Questions
- Longer-term clinical outcomes and investigational use require continued evaluation.
- Safety of combining Survodutide with other receptor agonists is not established.
- Clinical results do not establish the quality or stability of a research-market vial.
Survodutide Precautions
Avoid or discuss with a clinician if
- Known hypersensitivity to ingredients.
- Pregnancy, breastfeeding, or pediatric use outside appropriate medical oversight.
- Severe persistent abdominal pain, dehydration, or repeated vomiting needs medical evaluation.
Use caution with
- Insulin, sulfonylureas, and other glucose-lowering treatment.
- Significant gastrointestinal illness, advanced liver disease, or complex medication regimens.
Research status: Survodutide is investigational in the cited trials. The research program does not establish an approved self-directed treatment or a validated retail-vial protocol.
Final verdict
Peptide Protocols Verdict on Survodutide
Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.
Our opinionated opinion
Survodutide interests us because the liver program gives it a specific research story. Weight reduction is useful, but separating liver-fat changes from MASH and fibrosis makes the findings much more informative.
We also think tolerability deserves equal billing with the efficacy headline. A compound can produce meaningful results while being difficult for some participants to stay on. The different trial analyses help explain that gap.
Our B reflects substantial promise with practical questions still open. We would follow the ongoing clinical program closely and avoid treating the name as a reason to combine it with another GLP-1 or glucagon agonist.